UNSPSC 51124100: Antiarrythmic purines

This classification denotes heterocyclic pyrimidine-imidazole ring compounds present in many alkaloids and nucleic acids, substances called purines, that prevent or treat irregular heartbeat, disturbances of normal rhythmic heart beating, or normal operation of myocardial contraction, thus the term ANTIARRYTHMIC PURINES.

UNSPSC 51124100 Antiarrhythmic purines is a Class code covering antiarrhythmic medications supplied to emergency medical services, hospital systems, and state health agencies. State and local governments procure these drugs for use in advanced life support protocols, particularly adenosine and related compounds used in emergency cardiac care. Issuing bodies include city fire and rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The City of Tampa's fire rescue system, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the primary categories of buyers active under this code in recent months.

Recent activity appears concentrated in Florida and the upper Midwest, with exploratory procurement underway in Texas. The City of Tampa issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications including adenosine 6mg vials for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000, awarded to the lowest responsive bidder with a one-year term and two optional one-year renewals plus unilateral 30-day extensions. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription fulfillment, which suggests emerging state-level demand but does not yet establish a formal solicitation. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals including antiarrhythmic products across participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026, and a two-year initial term.